Drug Sponsors

Valeant acquires Visudyne from QLT

Tuesday, September 25, 2012 10:57 AM

Valeant Pharmaceuticals International, a multinational specialty pharmaceutical company, has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT.

More... »

Mallinckrodt to acquire CNS Therapeutics

Tuesday, September 25, 2012 10:31 AM

Mallinckrodt, the pharmaceuticals business of Covidien, a global healthcare products company, has agreed to acquire CNS Therapeutics, a St. Paul, Minn.-based specialty pharmaceutical company focused on neurological disorders and intractable chronic pain.

More... »

Novo Nordisk to expand R&D center in China

Tuesday, September 25, 2012 09:58 AM

Novo Nordisk, a Denmark-based biopharmaceutical company and the first multinational company to open a research center in China in 1997, is reaffirming its long-term commitment to the country by investing an additional $100 million to expand its state-of-the-art science facilities in Beijing.

More... »

GNS Healthcare, Covance to enable more efficient, cost-effective drug development

Friday, September 21, 2012 02:31 PM

GNS Healthcare, a Cambridge, Mass.-based healthcare data analytics company focused on enabling personalized medicine, has entered into a collaboration with global CRO Covance to develop novel data-driven models that will assist pharmaceutical companies in optimizing the efficiency and cost-effectiveness of drug development activities.

More... »

Progenics undergoes restructuring, cuts 26% of workforce

Friday, September 21, 2012 02:15 PM

Progenics Pharmaceuticals, a Tarrytown, N.Y.-based biopharmaceutical company focused on cancer and related conditions, has announced companywide restructuring, including a reduction of its workforce. The company will continue to focus its resources and efforts on its oncology programs, particularly an upcoming phase II study of PSMA ADC in prostate cancer patients.

More... »

Foundation Medicine completes $42.5M Series B financing

Friday, September 21, 2012 12:18 PM

Foundation Medicine, a Cambridge, Mass.-based molecular information company focused on bringing comprehensive cancer genomic analysis to routine clinical care, has completed a $42.5 million Series B financing.

More... »

MacroGenics, Servier to develop three anti-cancer DART products

Friday, September 21, 2012 11:56 AM

MacroGenics, a Rockville, Md.-based privately held biotech that develops next generation antibody therapeutics, and Servier, a privately-held French pharmaceutical company, have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets.

More... »

Third Rock launches MyoKardia with $38M for genetic heart disease

Friday, September 21, 2012 10:51 AM

Third Rock Ventures, a venture capital firm of Boston, Mass., has formed new company MyoKardia with a $38 million Series A financing. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

More... »

Boston Scientific to acquire BridgePoint Medical

Thursday, September 20, 2012 07:30 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, agreed to acquire BridgePoint Medical, a privately held company based in Minneapolis, Minn. The transaction is expected to close in the fourth quarter of 2012 subject to customary closing conditions.

More... »

AMRI forms strategic contract with Knopp Biosciences

Wednesday, September 19, 2012 03:18 PM

AMRI, a global contract research and manufacturing organization, has entered into a new strategic agreement with Knopp Biosciences, a Pittsburgh-based drug discovery and development company focused on breakthrough treatments for unmet needs in neurological disorders.  

More... »